TY  - JOUR
AU  - Faivre-Finn, Corinne
AU  - Spigel, David R
AU  - Senan, Suresh
AU  - Langer, Corey
AU  - Perez, Bradford A
AU  - Özgüroğlu, Mustafa
AU  - Daniel, Davey
AU  - Villegas, Augusto
AU  - Vicente, David
AU  - Hui, Rina
AU  - Murakami, Shuji
AU  - Paz-Ares, Luis
AU  - Broadhurst, Helen
AU  - Wadsworth, Catherine
AU  - Dennis, Phillip A
AU  - Antonia, Scott J
PY  - 2020
DO  - 10.1016/j.lungcan.2020.11.024
UR  - http://hdl.handle.net/10668/16748
T2  - Lung cancer (Amsterdam, Netherlands)
AB  - The PACIFIC trial demonstrated that durvalumab significantly improved progression-free and overall survival (PFS/OS), versus placebo, in patients with Stage III NSCLC and stable or responding disease following concurrent, platinum-based...
LA  - en
KW  - Chemoradiotherapy
KW  - Chemotherapy
KW  - Immunotherapy
KW  - Non-small-cell lung cancer
KW  - Radiotherapy
KW  - Antibodies, Monoclonal
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Chemoradiotherapy
KW  - Humans
KW  - Lung Neoplasms
TI  - Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
TY  - research article
VL  - 151
ER  -